title: Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy.
abstract: Cancer is a clonal malignant disease originated in a single cell and characterized by the accumulation of partially differentiated cells that are phenotypically reminiscent of normal stages of differentiation. According to current models, therapeutic strategies that block oncogene activity are likely to selectively target tumor cells. However, recent evidences have revealed that cancer stem cells could arise through a tumor stem cell reprogramming mechanism, suggesting that genetic lesions that initiate the cancer process might be dispensable for tumor progression and maintenance. This review addresses the impact of these results toward a better understanding of cancer development and proposes new approaches to treat cancer in the future.
authors: Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
authors: Carolina
authors: C
authors: Vicente-Dueñas
authors: Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
authors: Julia
authors: J
authors: Hauer
authors: Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
authors: Lucía
authors: L
authors: Ruiz-Roca
authors: Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
authors: Deborah
authors: D
authors: Ingenhag
authors: Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
authors: Alba
authors: A
authors: Rodríguez-Meira
authors: Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
authors: Franziska
authors: F
authors: Auer
authors: Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. Electronic address: Arndt.Borkhardt@med.uni-duesseldorf.de.
authors: Arndt
authors: A
authors: Borkhardt
authors: Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. Electronic address: isg@usal.es.
authors: Isidro
authors: I
authors: Sánchez-García
mesh_terms: D000818:Animals; D002454:Cell Differentiation / Q000235:genetics; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D065150:Cellular Reprogramming / Q000235:genetics*; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy; D014411:Neoplastic Stem Cells; D009857:Oncogenes / Q000235:genetics*
keywords: Cancer stem cell; Mouse model; Oncogenes; Stem cells; Tumoral reprogramming